Trevor Vanschooneveld, MD
Infectious Disease · Omaha, NENPI 1568544799
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,453 of the $56,245 with a category attached, or 68.4%. Biomerieux Inc accounts for 61.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $31,014 and has fallen 99.6% since, to $111 in 2025. Among infectious disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $1406.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomerieux Inc$34K
- Fisher Scientific Company L.L.C.$19K
- Biofire Diagnostics, LLC$2K
- Gilead$290
- Shionogi Inc$111
- Insmed, Inc.$66
- plus $30 from 1 others
Across 13 payments — averaging $12,781 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biofire Diagnostics, LLC$77K
- Merck$56K
- Mannkind Corporation$21K
- Ferring Pharmaceuticals AS$12K
What the payments were for
- Consulting fees$5,49010%
- Speaking & faculty fees$38,45368%
- Travel & lodging$11,67821%
- Food & beverage$5951%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomerieux Inc | 17 | $34,497 |
| Fisher Scientific Company L.L.C. | 16 | $19,087 |
| Biofire Diagnostics, LLC | 2 | $2,165 |
| Gilead | 1 | $290 |
| Shionogi Inc | 1 | $111 |
| Insmed, Inc. | 2 | $66 |
| Astellas Pharma US Inc | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FILMARRAY PNEUMONIA PANEL (PNEUMO)$12,902
- Procalcitonin$11,300
- VITEK2$7,801
- BRAHMS PCT KRYPTOR$7,787
- Film Array$2,125
- FILMARRAY RESPIRATORY PANEL (RP)$548
- Veklury$290
How this compares
$56,245 in reported general payments places this provider in the 90th percentile of 55 infectious disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 20 | $311,467 |
| NuzyraOmadacycline Tosylate | 13 | $50,851 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 99 | $29,113 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 139 | $28,321 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 45 | $12,828 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 60 | $3,480 |
| Ethambutol Hcl | 27 | $2,044 |
| Rifabutin | 14 | $1,773 |
| Rifampin | 20 | $1,349 |
| Azithromycin | 33 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $66 | $311,46720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 55 infectious disease providers in Nebraska.
Other infectious disease in Omaha
- Rudolf KotulaOmaha$221K
- Marvin BittnerOmaha$100K
- Mark RuppOmaha$76K
- Nada FadulOmaha$26K
- Alison FreifeldOmaha$15K
- Amir GholamiOmaha$12K
- Andre KalilOmaha$11K
- Kelly CawcuttOmaha$11K
- Diana FlorescuOmaha$11K
- Jeffrey SartinOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.